Healthy Life

Innovative development of the pharmaceutical and biotech industry in Russia: keys to success

07 Jun, 10:00–11:15
‘Healthy Life’ Programme
Pavilion G, ‘Healthy Life’ Area

Russian scientists have already demonstrated their successful medical and biotechnological projects to the global scientific community and business. Achieving leadership in this regard means developing broad internal expertise in managing R&D, shaping a culture of development within startups, having sources for their funding, integrating into the global network of joint research projects, developing one’s own expertise, and focusing on the international market. A successful ‘triple helix’ innovation concept has emerged in global practice, which entails collaboration between the government, research centres, and business. Global pharmaceutical and medical companies are increasingly employing a model of open innovation when creating and commercializing new products. What are the most successful models of innovation at pharmaceutical and medical companies? Which of them could be most effectively implemented in Russia? What is the role of the state and development institutions in creating conditions to realize the potential of advanced innovative development? How can investments be raised for Russian developments? What problems do developers and investors face? What are possible solutions?

Moderator
Yury Krestinskiy, Chief Executive Officer, Healthcare Industry, Sberbank

Panellists
Max Wegner, Senior Vice President, Head of Regulatory Affairs, Pharmaceuticals Division, Bayer AG
Arkady Dvorkovich, President, World Chess Federation (FIDE); Chairman, Skolkovo Foundation
Sergey Tsyb, First Deputy Minister of Industry and Trade of the Russian Federation

Front row participants
Alexey Basov, Deputy General Director – Investment Director, RVC
Daniela Drago, Director, Regulatory Affairs Programs, Clinical Research and Leadership, School of Medicine and Health Sciences, George Washington University
Andrey Zagorsky, General Director, National Immunobiological Company
Vasily Ignatiev, General Director, R-Pharm
Vadim Kukava, Executive Director, Innovative Pharma Association of Pharmaceutical Companies
Ayrat Farrakhov, Deputy, Member of the Committee on Budget and Taxes, State Duma of the Federal Assembly of the Russian Federation
Vladimir Shipkov, Executive Director, Association of International Pharmaceutical Manufacturers (AIPM)

Broadcast